Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 28%
Buy 28%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc is positioned favorably in the biopharmaceutical sector, primarily driven by the ongoing success of its flagship drug cabozantinib (Cabo), which is gaining traction in renal cell carcinoma (RCC) and showing promise in neuroendocrine tumors (NETs) following recent label expansions. Additionally, the combination therapy of zanzalintinib with atezolizumab has demonstrated statistically significant improvements in median overall survival, further solidifying the company's portfolio in targeted cancer therapies. The company's ability to generate continued positive data outcomes and expand treatment indications supports a robust outlook for future growth and market performance.

Bears say

Exelixis, Inc. faces significant financial headwinds due to an anticipated 80% decline in revenues following the patent expiration of its key product, cabozantinib, by 2031, a forecast more severe than the market consensus of 68% reduction. Additionally, the company is exposed to competitive risks, including market share erosion for cabozantinib in renal cell carcinoma (RCC) and potential failures in approval timelines for other treatments in its pipeline, particularly zanzalintinib. Ultimately, these factors have led to concerns regarding the sustainability of revenue growth and overall share valuation, warranting a cautious outlook on the company's future financial performance.

Exelixis (EXEL) has been analyzed by 18 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 28% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 18 analysts, Exelixis (EXEL) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.